Navigation Links
Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease
Date:3/1/2010

VOORHEES, N.J., March 1 /PRNewswire/ -- Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC are lacking and healthcare professionals must consider several factors, including serum markers, patient age and pre-existing comorbidities when choosing between second-line hormonal therapy and chemotherapy for treatment of CRPC. It is critical for healthcare professionals involved in the care of patients with CRPC to understand and utilize the current optimal methods for defining, assessing and treating this condition.

To address the need for current education on CRPC, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education live Webcast titled Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease on Thursday March 25, 2010 from 12:00 PM to 1:00 PM ET. This activity, which is supported by educational grants from sanofi aventis and Genentech, is certified for physicians, pharmacists and nurses.

Robert Dreicer, MD, MS, FACP, Chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine in Cleveland, OH will serve as expert faculty for this live Webcast.

Healthcare professionals can register today by visiting www.ProstateEducation.com.

RMEI is a medical education company that specializes in independent, continuing medical education designed for clinicians to improve and deliver quality medical care to patients. The goal of RMEI educational offerings is to promote continuous professional development and the improvement of health outcomes. RMEI works closely with medical experts to develop activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.RMEI.com.

SOURCE Robert Michael Educational Institute LLC

Back to top

RELATED LINKS
http://www.RMEI.com

'/>"/>

SOURCE Robert Michael Educational Institute LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Source Vitál Apothecary, a skin and body care company dedicated ... company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition ... in the nutritional, sports and health industries a chance to meet in private sessions ...
(Date:1/20/2017)... ... 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to ... a successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports ... to provide its products to all clients at reasonable prices. At the ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Michael and Betsy ... Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as she ... not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The ... 233.7 billion by 2025, according to a new ... is anticipated to be predominantly driven by high ... into the large-scale production of new and therapeutically ... influx of drugs at an unprecedented rate into ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda ... will release results for the fourth quarter of 2016 on Wednesday, ... ... at 4:30 PM ET on Wednesday, February 15, 2017, during which ... results and other corporate activities. To participate in the conference call, ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: